Pravastatin attenuates cardiac dysfunction induced by lysophosphatidylcholine in isolated rat hearts

European Journal of Pharmacology

Volumn 640, Issue 1-3, 2010, Pages 139-142

  Li, Libing ^a   Yao, Yuntai ^b   Wang, Hongye ^a   Ren, Yihong ^a   Ma, Lan ^a   Yan, Junlan ^a   Gao, Changqing ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Cardiac dysfunction; Endothelin 1; Lysophosphatidylcholine; Pravastatin; Ventricular arrhythmias

Indexed keywords

BIOLOGICAL MARKER; CREATINE KINASE MB; ENDOTHELIN 1; LACTATE DEHYDROGENASE; LYSOPHOSPHATIDYLCHOLINE; PRAVASTATIN;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY BLOOD FLOW; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; HEART DISEASE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; HEART; HEART VENTRICLE; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TACHYCARDIA; VENTRICULAR FIBRILLATION;

ANIMALS; CREATINE KINASE, MB FORM; ENDOTHELIN-1; HEART; HEART VENTRICLES; HEMODYNAMICS; L-LACTATE DEHYDROGENASE; LYSOPHOSPHATIDYLCHOLINES; MALE; PRAVASTATIN; RATS; RATS, SPRAGUE-DAWLEY; TACHYCARDIA; VENTRICULAR FIBRILLATION;

EID: 77953808438     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.052     Document Type: Article

References (26)

1. Del Sol A.I., Nanayakkara P.W. Pravastatin: an evidence-based statin?. Expert. Opin. Drug Metab. Toxicol. 2008, 4:821-825.
2. Feng M., Liu L.H., Guo Z., Xiong Y. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine. Eur. J. Pharmacol. 2008, 584:49-56.
3. Hashizume H., Hoque A.N., Magishi K., Hara A., Abiko Y.A. A new approach to the development of anti-ischemic drugs. Substances that counteract the deleterious effect of lysophosphatidylcholine on the heart. Jpn. Heart J. 1997, 38:11-25.
4. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 1998, 101:2711-2719.
5. Hoque A.N.E., Hoque N., Hashizume H., Abiko Y. A study on dilazep: II. Dilazep attenuates lysophosphatidylcholine-induced mechanical and metabolic derangements in the isolated, working rat heart. Jpn. J. Pharmacol. 1995, 67:233-241.
6. Kang J.X., Leaf A. Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. Eur. J. Pharmacol. 1996, 297:97-106.
7. Li L.B., Matsuoka I., Suzuki Y., Watanabe Y., Ishibashi T., Yokoyama K., Maruyama Y., Kimura J. Inhibitory effect of fluvastatin on lysophosphatidylcholine-induced nonselective cation current in Guinea pig ventricular myocytes. Mol. Pharmacol. 2002, 62:602-607.
8. Liu E., Goldhaber J.I., Weiss J.N. Effects of lysophosphatidylcholine on electrophysiological properties and excitation-contraction coupling in isolated guinea-pig ventricular myocytes. J. Clin. Invest. 1991, 88:1819-1832.
9. Magishi K., Kimura J., Kubo Y., Abiko Y. Exogenous lysophosphatidylcholine increases non-selective cation current in guinea-pig ventricular myocytes. Pflügers Arch. Eur. J. Physiol. 1996, 432:345-350.
10. Man R.Y. Lysophosphatidylcholine-induced arrhythmias and its accumulation in the rat perfused heart. Br. J. Pharmacol. 1988, 93:412-416.
11. Mitsutomi N., Akashi C., Odagiri J., Matsumura Y. Effects of endogenous and exogenous nitric oxide on endothelin-1 production in cultured vascular endothelial cells. Eur. J. Pharmacol. 1999, 364:65-73.
12. Miyauchi T., Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu. Rev. Physiol. 1999, 61:391-415.
13. Morikawa S., Takabe W., Mataki C., Kanke T., Itoh T., Wada Y., Izumi A., Saito Y., Hamakubo T., Kodama T. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J. Atheroscler. Thromb. 2002, 9:178-183.
14. Neufeld K.J., Lederman C.L., Choy P.C., Man R.Y. The effect of lidocaine on lysophosphatidylcholine-induced cardiac arrhythmias and cellular disturbances. Can. J. Physiol. Pharmacol. 1985, 63:804-808.
15. Ohkita M., Takaoka M., Sugii M., Shiota Y., Nojiri R., Matsumura Y. The role of nuclear factor-κB in the regulation of endothelin-1 production by nitric oxide. Eur. J. Pharmacol. 2003, 472:159-164.
16. Peters B., Maitland-van Z.A.H. Pharmacogenomic importance of pravastatin. Pharmacogenomics 2008, 9:1207-1210.
17. Saegent C.A., Vesterqvist O., Ogletree M.L., Grover G.J. Effects of endogenous and exogenous lysophosphatidylcholine in isolated perfused rat heart. J. Mol. Cell. Cardiol. 1993, 25:905-913.
18. 2+ accumulation in rat cardiac myocytes. Am. J. Physiol. 1983, 244:H32-H38.
19. Sedlis S.P., Sequeira J.M., Altszuler H.M. Coronary sinus lysophosphatidylcholine accumulation during rapid atrial pacing. Am. J. Cardiol. 1990, 66:695-698.
20. Sedlis S.P., Hom M., Sequeira J.M., Tritel M., Gindea A., Ladenson J.H., Jaffe A.S., Esposito R. Time course of lysophosphatidylcholine release from ischemic human myocardium parallels the time course of early ischemic ventricular arrhythmia. Coron. Artery Dis. 1997, 8:19-27.
21. Shaikh N.A., Downer E. Time course of changes in porcine myocardial phospholipid levels during ischemia. Circ. Res. 1981, 49:316-325.
22. Sobel B.E., Corr P.B., Robison A.K., Goldstein R.A., Witkowski F.X., Klein M.S. Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium. J. Clin. Invest. 1978, 62:546-553.
23. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1712-1719.
24. 2+-overload in isolated cardiomyocytes and effect of cytoprotective drugs. J. Mol. Cell. Cardiol. 1992, 24:977-988.
25. Watanabe T., Pakala R., Katagiri T., Benedict C.R. Lysophosphatidylcholine is a major contributor to the synergistic effect of mildly oxidized low-density lipoprotein with endothelin-1 on vascular smooth muscle cell proliferation. J. Cardiovasc. Pharmacol. 2002, 39:449-459.
26. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.